OncoSec Medical Incorporated
MODULATING RESPONSES TO CHECKPOINT INHIBITOR THERAPY
Last updated:
Abstract:
The present invention provides for a dosing schedule for the intratumoral delivery of an immunostimulatory cytokine in combination with systemic delivery of a checkpoint inhibitor. In particular, it provides delivery of a plasmid encoding the immunostimulatory cytokine, e.g., IL-12, using intratumoral electroporation, and the systemic delivery of a PD-1 antagonist.
Status:
Application
Type:
Utility
Filling date:
4 Jan 2021
Issue date:
2 Dec 2021